🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

A Global Challenge

Gonorrhoea infections are increasing around the world, with estimates suggesting in excess of 82 million infections each year. Notably increased rates are observed in the African continent and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the context of growing infection rates, the spread of superbugs and the very limited treatment choices currently available.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This drug, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for drug creation. The charitable organization GARDP collaborated with the drug firm its industry partner to see it through.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Research Study Results and Global Access

As per findings published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This establishes an comparable level with the current standard treatment, which uses an injection and a pill. The trial involved hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have expressed hope. Access to a one-pill regimen such as this is described as a "revolutionary step" for public health efforts. This is considered essential to lessen the impact of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.